Samsung Biologics union workers began a five-day strike over wage disputes, after a prior April rally and near-unanimous strike authorization. With production disruption risk now moving from negotiation to operations, large-scale biologics supply continuity becomes the immediate concern for customers running clinical and commercial manufacturing schedules. The walkout highlights how labor negotiations can quickly become a supply-chain variable for contract manufacturing organizations, especially where capacity is heavily scheduled. For biotech, the operational stability of CDMO production lines remains critical during ongoing pipeline transitions. Companies relying on Samsung’s manufacturing footprint may need to reassess batch timing, logistics, and contingency planning as the strike unfolds.